Hypercoagulable State in COVID-19 and Diabetes: Cerebral Vasospasm, Intracardiac Clot, and Pulmonary Embolism
DOI:
https://doi.org/10.60787/njgp.v20i1.6Keywords:
vasospasm, thrombus, pulmonary embolism, diabetes, COVID-19, CoagulationAbstract
Background: Hypercoagulable state in the form of venous and arterial thromboembolism, associated with poor prognosis, could be a severe sequel of COVID‑19 infections. We present representative cases that show hypercoagulable state in COVID‑19 and the negative effects of diabetes and age on outcomes of anticoagulation therapy. Our aim is to understand the role of predisposing factors for the successful use of anticoagulants.
Methods: We applied clinical history, examination, laboratory tests, noninvasive ultrasound imaging, and computer-assisted tomography to characterize hypercoagulable state in patients with COVID-19.
Results: One patient (83 years) was diabetic of the elderly group (>64 years), who developed sepsis-induced coagulopathy (SIC), cerebral arterial vasospasm, intracardiac clots, coronary ischemia, and pulmonary embolism with fatal outcome despite the use of anticoagulation. The second patient (60 years) was diabetic of the middle-age group (48–63 years), who developed SIC, cerebral arterial vasospasm, intracardiac clots, and coronary ischemia and had good outcome with the use of anticoagulation. The third case was a patient(22 years) without diabetes of the youth group (15–47 years) who developed cardiomyopathy, heart valve vegetations, and cerebral arterial vasospasm, received anticoagulation, and had good outcome. The difference in outcome with the application of anticoagulation with lower molecular weight heparin could be related to the greater burden of disease including diabetes, age, and chronic obstructive pulmonary disease.
Conclusion: Noninvasive ultrasound imaging modalities in combinations with computed axial tomography scans provided insightful characterization of the hypercoagulable state of COVID-19 infection, which helped guide therapeutic intervention.
Downloads
References
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet 2020;395:1054-62.
Guan, WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med
;382:1708-20.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
;395:497-506.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus
pneumonia. J Thromb Haemost 2020;18:844-7.
Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.
LlitjosJF, LeclercM, ChochoisC, MonsallierJM, RamakersM, AuvrayM, et al. High incidence of venous thromboembolic events in anticoagulated
severe COVID-19 patients. J Thromb Haemost 2020;18:1743-6.
Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation
;141:1739-41.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417-8.
Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud T, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the national institute for public health of the Netherlands. Radiology 2020;297:E216-22.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease
patients with coagulopathy. J Thromb Haemost 2020;18:1094-9.
Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem
Lab Med 2020;58:1116-20.
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020;191:9-14.
Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in
patients with COVID-19: A prospective cohort study. Ann Intern Med 2020;173:268-77.
Menter T, HaslbauerJD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Postmortem examination of COVID‑19 patients reveals diffuse
alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction.
Histopathology 2020;77:198-209.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and
angiogenesis in COVID-19. N Engl J Med 2020;383:120-8.
Landstra CP, de Koning EJ. COVID-19 and diabetes: Understanding the interrelationship and risks for a severe course. Front Endocrinol (Lausanne) 2021;12:649525.
Stegenga ME, van der Crabben SN, Blümer RM, Levi M, Meijers JC, Serlie MJ, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008;112:82-9.
Lang RM, Badano LP, Mor‑Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-71.
Liboni W, Allais G, Mana O, Molinari F, Grippi G, Negri E, et al.Transcranial Doppler for monitoring the cerebral blood flow dynamics: Normal ranges in the Italian female population. Panminerva Med 2006;48:187-91.
Samagh N, Bhagat H, Jangra K. Monitoring cerebral vasospasm: How much can we rely on transcranial Doppler. J Anaesthesiol Clin Pharmacol 2019;35:12-8.
Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 2020;194:101-15.
Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020;22:95-7.
Dunn E, Grant P. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005;5:323-32.
Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813-21.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab
Res Rev 2020;36:1-9.
Published
Issue
Section
License
Copyright (c) 2024 Nigerian Journal of General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
